Insider Buying: Context Therapeutics Inc. (NASDAQ:CNTX) Insider Acquires 20,000 Shares of Stock

Context Therapeutics Inc. (NASDAQ:CNTX) insider Alex C. Levit bought 20,000 shares of the company’s stock in a transaction dated Friday, June 6th. The stock was bought at an average cost of $0.58 per share, with a total value of $11,600.00. Following the acquisition, the insider now directly owns 29,000 shares of the company’s stock, valued at approximately $16,820. The trade was a 222.22% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Context Therapeutics Stock Performance

Context Therapeutics stock opened at $0.65 on Friday. Context Therapeutics Inc. has a 52-week low of $0.49 and a 52-week high of $2.75. The firm has a 50 day moving average price of $0.75 and a two-hundred day moving average price of $0.91. The firm has a market cap of $58.54 million, a price-to-earnings ratio of -0.72 and a beta of 1.86.

Context Therapeutics (NASDAQ:CNTX) last released its quarterly earnings results on Wednesday, May 14th. The company reported ($0.05) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.05). As a group, equities research analysts predict that Context Therapeutics Inc. will post -0.51 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have recently commented on CNTX shares. William Blair reissued an “outperform” rating on shares of Context Therapeutics in a report on Tuesday, April 29th. HC Wainwright reiterated a “buy” rating and issued a $5.00 price objective on shares of Context Therapeutics in a report on Friday, March 21st. Finally, D. Boral Capital reiterated a “buy” rating and issued a $9.00 price objective on shares of Context Therapeutics in a report on Thursday, May 8th. Four investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Context Therapeutics currently has a consensus rating of “Buy” and an average price target of $6.00.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Jane Street Group LLC bought a new position in Context Therapeutics during the 4th quarter worth approximately $29,000. Citadel Advisors LLC acquired a new stake in shares of Context Therapeutics during the 4th quarter worth approximately $31,000. Shay Capital LLC acquired a new stake in shares of Context Therapeutics during the 4th quarter worth approximately $52,000. Landscape Capital Management L.L.C. acquired a new stake in shares of Context Therapeutics during the 4th quarter worth approximately $94,000. Finally, Walleye Capital LLC grew its position in shares of Context Therapeutics by 51.7% during the 4th quarter. Walleye Capital LLC now owns 166,306 shares of the company’s stock worth $175,000 after buying an additional 56,651 shares during the period. Institutional investors own 14.03% of the company’s stock.

Context Therapeutics Company Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.